2022;7(1):bvac172
On the other hand, Mounjaro has 6 strengths, starting from 2.5 mg, and 3 maintenance dosages: 5 mg, 10 mg, and 15 mg
Regulatory Status, Reported Safety Signals, and Why This Is Not a Treatment Plan Retatrutide is not FDA-approved for weight management or any other use, and never has been
For Peyronie's disease : 1 gram of acetyl-L-carnitine has been taken twice daily for 3 months
Second, existing GLP-1 medications like semaglutide already have approval for type 2 diabetes, so retatrutide would be entering a market with established competitors but potentially superior efficacy
The realistic timeline: pivotal trial results by mid-2026, NDA submission by late 2026, FDA decision by mid to late 2027, and pharmacy availability by late 2027 or early 2028